Profile data is unavailable for this security.
About the company
AbbVie Inc. is a research-based biopharmaceutical company, which is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta; aesthetics products that include Botox Cosmetic, Juvederm Collection and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products consists of Lumigan, Alphagan and Restasis; women's health products include Lo Loestrin, Orilissa and others; and other products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. Its products are sold to wholesalers, government agencies, health care facilities and independent retailers. It also discovers and develop antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).
- Revenue in USD (TTM)57.82bn
- Net income in USD13.34bn
- Incorporated2012
- Employees50.00k
- LocationAbbvie Inc1 N Waukegan RdNORTH CHICAGO 60064United StatesUSA
- Phone+1 (847) 932-7900
- Fax+1 (302) 655-5049
- Websitehttps://www.abbvie.com/
Mergers & acquisitions
| Acquired company | ABBV:NYQ since announced | Transaction value |
|---|---|---|
| DJS Antibodies Ltd | 10.87% | 255.00m |
| iSTAR Medical SA | 5.98% | 475.00m |
| Syndesi Therapeutics SA | 7.39% | 1.00bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen, Inc. | 26.33bn | 6.84bn | 150.80bn | 24.20k | 22.64 | 41.28 | 14.79 | 5.73 | 12.48 | 12.48 | 48.09 | 6.85 | 0.4092 | 1.43 | 5.22 | 1,088,017.00 | 10.62 | 11.07 | 13.74 | 13.40 | 75.78 | 79.29 | 25.96 | 30.88 | 1.35 | 7.70 | 0.9138 | 49.28 | 2.18 | 2.47 | -18.87 | -5.26 | 1.01 | 11.97 |
| Bristol-Myers Squibb Co | 46.74bn | 6.68bn | 168.26bn | 32.20k | 25.80 | 5.15 | 9.88 | 3.60 | 3.07 | 3.07 | 21.53 | 15.38 | 0.4471 | 4.65 | 5.72 | 1,451,491.00 | 6.40 | 2.67 | 7.94 | 3.29 | 78.91 | 74.18 | 14.32 | 6.54 | 1.31 | 4.49 | 0.5443 | 163.84 | 9.09 | 19.01 | 177.58 | 9.43 | -4.35 | 5.22 |
| Merck & Co Inc | 58.97bn | 15.32bn | 274.96bn | 68.00k | 17.97 | 6.18 | 14.33 | 4.66 | 6.04 | 6.01 | 23.23 | 17.55 | 0.588 | 3.06 | 6.53 | 867,264.70 | 15.29 | 7.61 | 19.95 | 10.14 | 70.85 | 70.92 | 26.00 | 16.06 | 1.22 | 10.49 | 0.4059 | 86.06 | 17.31 | 4.12 | 173.18 | 25.79 | 22.48 | 7.49 |
| Pfizer Inc. | 99.68bn | 30.23bn | 278.25bn | 79.00k | 9.40 | 3.00 | 7.93 | 2.79 | 5.27 | 5.19 | 17.37 | 16.51 | 0.5323 | 3.79 | 7.13 | 1,261,722.00 | 16.15 | 6.62 | 21.01 | 8.25 | 65.51 | 74.04 | 30.35 | 21.32 | 1.37 | 16.56 | 0.283 | 75.72 | 95.16 | 9.00 | 238.05 | 25.51 | 6.28 | 5.39 |
| AbbVie Inc | 57.82bn | 13.34bn | 280.18bn | 50.00k | 21.11 | 17.52 | 12.91 | 4.85 | 7.51 | 7.51 | 32.54 | 9.04 | 0.3985 | 5.32 | 5.77 | 1,156,380.00 | 9.25 | 7.46 | 11.73 | 9.46 | 71.16 | 72.03 | 23.21 | 18.11 | 0.8313 | 8.81 | 0.8128 | 97.89 | 22.69 | 16.99 | 151.71 | 14.13 | 10.44 | 17.93 |
| Eli Lilly And Co | 29.24bn | 6.03bn | 347.55bn | 35.00k | 54.97 | 34.51 | 45.57 | 11.89 | 6.65 | 6.65 | 32.27 | 10.60 | 0.6114 | 1.84 | 4.63 | 835,414.30 | 12.62 | 11.08 | 18.28 | 15.80 | 75.61 | 77.16 | 20.63 | 20.77 | 0.8822 | 8.19 | 0.6098 | 53.75 | 15.40 | 5.94 | -9.88 | 15.31 | 11.40 | 10.76 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2022 | 148.48m | 8.40% |
| BlackRock Fund Advisorsas of 30 Sep 2022 | 85.68m | 4.85% |
| SSgA Funds Management, Inc.as of 30 Sep 2022 | 77.49m | 4.38% |
| Capital Research & Management Co. (International Investors)as of 30 Sep 2022 | 45.83m | 2.59% |
| JPMorgan Investment Management, Inc.as of 30 Sep 2022 | 41.38m | 2.34% |
| Capital Research & Management Co. (Global Investors)as of 30 Sep 2022 | 36.19m | 2.05% |
| Geode Capital Management LLCas of 30 Sep 2022 | 33.83m | 1.91% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 30 Sep 2022 | 24.52m | 1.39% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2022 | 21.85m | 1.24% |
| Norges Bank Investment Managementas of 31 Dec 2021 | 17.97m | 1.02% |
